יחס שווי פעילות לרווח לפני ריבית, מסים ופחת InspireMD Inc. (NSPR)

Serving as the primary valuation tool, this InspireMD, Inc. (NSPR) price chart demonstrates an EV/EBITDA of 0.00, while global sales leave the company dependent on supply chain stability and exchange rates. The business relies on exclusive stroke-protection technologies, maintaining an advantage in the EU and awaiting approval in the US. Zero employee churn is ensured by the engineers' dedication to the coronary stents they develop.

This metric aggregates the market value and net debt of InspireMD, Inc. (NSPR), comparing them against operating profit before depreciation and amortization to determine the asset's real price. By analyzing the EV/EBITDA chart, a conservative investor can assess whether the premium pricing of InspireMD, Inc. (NSPR) unique stents justifies the current debt load and overall business capitalization over the long term.